European Urology Focus has accepted a scientific article describing LIDDS Phase IIb study results with Liproca® Depot
UPPSALA, SWEDEN – LIDDS AB (publ) announces that a scientific article will be published in the highly ranked European Urology Focus describing LIDDS clinical Phase IIb study, LPC-004, and its clinical results. The study met both primary and secondary endpoints by confirming efficacy and safety with Liproca Depot given as intraprostatic injection in low- and intermediate risk prostate cancer patients.
“We are pleased that this manuscript is accepted in a highly recognized scientific paper and the results further validates NanoZolid® as being an innovative technology platform,” said Monica Wallter, CEO of LIDDS.
Liproca Depot, which comprises the NanoZolid technology combined with an antiandrogen drug (2-hydroxyflutamide) injected into the prostate, met both the primary and secondary endpoints in the study. Efficacy was shown by a maintained PSA decrease over 6 months, lower prostate volume and unchanged or improved MRI results. No hormonal side effects were shown. LIDDS concludes that Liproca® Depot can be a new potential local treatment that is effective in controlling cancer for intermediate risk patients under “Active Surveillance”. The manuscript has the title “Liproca Depot – A new antiandrogen treatment for active surveillance patients" and is planned to be published on the European Urology Focus webpage during February.
“The results confirm that Liproca® Depot can offer a completely novel approach to complement active surveillance in intermediate risk prostate cancer patients. Liproca® Depot is well tolerated without the hormonal side effects otherwise associated with anti-androgen therapy and is equally easy to administer as performing a prostate biopsy. Liproca® Depot treatment could contribute to the benefit of prostate cancer patients in the future, says Professor Laurence Klotz, a world leading expert and one of the study investigators and Professor at the University of Toronto Division of Urology.
The NanoZolid® technology has during the last years been shown to enable a local controlled release of a wide range of drugs following a single injection, resulting in stable and pharmacologically relevant effects over the desired time-period, to overcome issues with systemic adverse effects or local frequent treatments. LIDDS has active projects where NanoZolid is successfully combined with cytotoxic- and immune modulating compounds with the intention to treat solid cancer tumors.
About the LPC-004 study
The LPC-004 study was a single blind, two-part dose finding study aimed to determine the highest tolerable dose of Liproca® Depot and to determine the level of PSA reduction for part II patients at month 5 (primary endpoints). The study was conducted at specialist urology clinics in Canada, Lithuania and Finland. The study involved 61 patients diagnosed with localized non-aggressive prostate cancer who were on Active Surveillance. Patients were followed for six months to assess response and tolerability. Following the LPC-004 study, a voluntary open label extension study was initiated offering patients a second injection of Liproca® Depot once the patient’s PSA level had returned to its pre-treatment level. Results showed that 50 % of the patients in the open label extension study remained at low PSA levels for at least 10 months from their first Liproca® Depot injection and were therefore not treated with a second injection.
For more information, please contact:
Monica Wallter, CEO, +46 (0)737 07 09 22, e-mail: email@example.com
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects for cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North (LIDDS). Redeye AB is the Certified Adviser to LIDDS (+46 (0) 8 121 576 90, email: firstname.lastname@example.org) For more information, please visit www.liddspharma.com.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
CrossAmerica Partners Files 2020 Annual Report on Form 10-K2.3.2021 22:15:00 CET | Press release
Allentown, March 02, 2021 (GLOBE NEWSWIRE) -- CrossAmerica Partners Files 2020 Annual Report on Form 10-K ALLENTOWN, PA, March 2, 2021 – CrossAmerica Partners LP (NYSE: CAPL) on March 2, 2021 has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 with the U.S. Securities and Exchange Commission (SEC). The filing can be viewed through a link on the Partnership's website at www.crossamericapartners.com or on the SEC's website at www.sec.gov. The Partnership's unitholders may request a printed copy of the report, which contains the Partnership's audited financial statements. Requests should be submitted at https://caplp.gcs-web.com/shareholder-services/document-request https://caplp.gcs-web.com/shareholder-services/document-request or by contacting investor relations at 610-625-8000. About CrossAmerica Partners LP CrossAmerica Partners is a leading wholesale distributor of motor fuels, convenience store operator and owner and lessor of real estate used in the
NEP Group Acquires VISTA Worldlink, Expanding Centralized Production Capabilities in the US and Worldwide2.3.2021 21:42:50 CET | Press release
NEP plans to create the first large-scale, end-to-end Centralized Production solution in the US and expand its facilities and capabilities around the globe. PITTSBURGH, March 02, 2021 (GLOBE NEWSWIRE) -- NEP Group, the leading worldwide outsourced technical production partner for premier content producers of live sports and entertainment, announced that it has acquired VISTA Worldlink(“VISTA”), a pioneer in providing centralized broadcast solutions since 2017. The acquisition supports NEP’s strategic goal of becoming the worldwide leader in Centralized (Remote) Production. Founded by industry veteran Roy Liemer in 1988, VISTA provides end-to-end workflows, transmission and connectivity, and packaged traditional broadcast production solutions to customers in sports, entertainment, news, corporate and a range of other industries, covering thousands of events in North America each year as well as Europe. The broadcast industry is evolving, and NEP is evolving, too, to help content produce
RCI Banque : RCI Banque discloses updated binding MREL requirement2.3.2021 19:30:00 CET | Press release
Tuesday, March 2nd, 2021 RCI Banque discloses updated binding MREL (1) requirement RCI Banque has received the notification from ACPR, the French Prudential and Resolution Supervision Authority, implementing the decision of the Single Resolution Board (SRB) and discloses its updated binding minimum requirement for own funds and eligible liabilities (MREL(1)). MREL requirement is no longer defined on consolidated basis but has been set on an individual basis for both RCI Banque S.A and its French subsidiary DIAC S.A. RCI Banque S.A. MREL requirement has been set at 8% of total risk exposure amount (TREA(2)) and 3% of leverage ratio exposure (LRE(3)) As of today, RCI Banque S.A. already complies with this MREL requirement. Future requirements will be subject to ongoing review. (1) MREL: Minimum Requirement for own funds and Eligible Liabilities. The Bank Recovery and Resolution Directive (BRRD) requires European banks to maintain a minimum amount of Own Funds and Eligible Liabilities tha
DIAC : DIAC discloses binding MREL requirement2.3.2021 19:30:00 CET | Press release
Tuesday, March 2nd, 2021 DIAC discloses binding MREL (1) requirement DIAC S.A. has received the notification from ACPR, the French Prudential and Resolution Supervision Authority, implementing the decision of the Single Resolution Board (SRB) and discloses its binding minimum requirement for own funds and eligible liabilities (MREL(1)). MREL requirement is no longer defined on RCI Group consolidated basis but has been set on an individual basis for both RCI Banque S.A and its French subsidiary DIAC S.A. DIAC S.A. MREL requirement has been set at 8% of total risk exposure amount (TREA(2)) and 3% of leverage ratio exposure (LRE(3)) As of today, DIAC S.A. already complies with this MREL requirement. Future requirements will be subject to ongoing review. (1) MREL: Minimum Requirement for own funds and Eligible Liabilities. The Bank Recovery and Resolution Directive (BRRD) requires European banks to maintain a minimum amount of Own Funds and Eligible Liabilities that could absorb losses and
Recording of the Fourth Quarter 2020 Investor Conference Webinar2.3.2021 19:05:00 CET | Press release
On March 2, 2021 JSC Olainfarm organized its Investor Conference Online Webinar. During the webinar Chairperson of Management Board Jeroen Weites and member of the management board Zane Kotāne analyzed the financial results of fourth quarter and 12 months 2020 and informed about other recent activities within the company. The recorded webinar is available online: https://bit.ly/3kBxkw4; and the presentation, demonstrated during the webinar, is available in the attachment. Methodology for alternative performance indicators is disclosed in Annual report for 2020 (page 15). Olainfarm thanks all participants, who joined the webinar, and encourages everybody to follow company’s announcements to get information on the next webinar! JSC Olainfarm, a part of Olainfarm Group, is one of the leading pharmaceutical companies in the Baltic States offering high quality medicine and chemical pharmaceutical products. The business strategy “FORWARD” highlights the company’s main vision – to become one
Feedzai recognized in NowTech: Enterprise Fraud Management, Q1 2021 Report2.3.2021 17:46:42 CET | Press release
SAN MATEO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Feedzai, the world’s leading cloud-based risk management platform announced today that it has been recognized in Forrester’s NowTech: Enterprise Fraud Management, Q1 2021 report. The report provides an overview of 37 Enterprise Fraud Management (EFM) providers. The report is designed to help security and risk professionals understand the value they can expect from an EFM provider, while also providing guidance on selecting vendors based on their respective expertise. In addition, the report addresses critical elements in EFM solutions that reduce fraud, minimize customer friction, and provide explainable fraud models - an increasingly important element as Responsible AI discussions take place from a regulatory perspective. “The days of closed risk scoring models for fraud management are over,” writes Andras Cser, Vice President, and Principal Analyst - Security and Risk Management at Forrester Research in the report:“EFM solutions h
Karolinska Development’s portfolio company OssDsign announces a fully guaranteed rights issue and launches new corporate strategy2.3.2021 17:02:24 CET | Press release
STOCKHOLM, SWEDEN – March 2, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company OssDsign has decided to carry out a fully guaranteed rights issue of SEK 240 million in combination with overallotment options of up to approximately SEK 30 million – a total of approximately SEK 270 million. The purpose of the financing is, among other things, to accelerate the company's development through the new strategy program ASCENT25. The guarantors of the rights issue include several of the company's previous major shareholders, including Karolinska Development, SEB Venture Capital and Fouriertransform. In connection with the rights issue, OssDsign presents a new corporate strategy with the purpose of realizing its potential and accelerating the development towards a positive cash flow by 2025. The great interest in the issue reflects confidence in OssDsign's capacity to advance to a new level. The new strategy, ASCENT25, aims to accelerate the compa